Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Ke Zhang, Xiangyi Kong, Yuan Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 25

Showing 25 citing articles:

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications
Miguel Á. Ortega, Diego Liviu Boaru, Diego De León-Oliva, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 8, pp. 987-1000
Closed Access | Times Cited: 12
Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug
Alice Njolke Mafe, Dietrich Büsselberg
Biomedicines (2025) Vol. 13, Iss. 2, pp. 422-422
Open Access | Times Cited: 1
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
Kavina Shah, Maria Leandro, Mark S. Cragg, et al.
Clinical & Experimental Immunology (2024) Vol. 217, Iss. 1, pp. 15-30
Open Access | Times Cited: 6
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Combining immune checkpoints with TNFSF agonists: a new horizon for cancer and autoimmune therapies
Lele Sun, Cuiping Li, Tingting Gao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
Samaneh Moradi, Pedram Sarikhani, Rafid Jihad Albadr, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment
Nasim Adabi, Safoora Pordel, Mohammad Ali Rezaee, et al.
The Journal of Gene Medicine (2023) Vol. 25, Iss. 5
Closed Access | Times Cited: 11
AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer
Ke Zhang, Yuan Li, Xiangyi Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 2033-2033
Open Access | Times Cited: 7
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications
Mai Ho, Benjamin Bonavida
Cells (2024) Vol. 13, Iss. 10, pp. 864-864
Open Access | Times Cited: 2
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Alf Spitschak, Shailendra K. Gupta, Krishna P. Singh, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 83-83
Open Access | Times Cited: 11
Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists
Renata Pacholczak‐Madej, Joanna Kosałka-Węgiel, Piotr Kuszmiersz, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 6, pp. 4926-4926
Open Access | Times Cited: 4
New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
Meijun Yue, Chunyu Li, Guohui Li
International Immunopharmacology (2024) Vol. 131, pp. 111799-111799
Closed Access | Times Cited: 1
Stat5b/Ezh2 axis governs high PD-L1 expressing tolerogenic dendritic cell subset in autoimmune diabetes
Farhan Ullah Khan, Puregmaa Khongorzul, Denis Gris, et al.
International Immunopharmacology (2024) Vol. 133, pp. 112166-112166
Closed Access | Times Cited: 1
Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management
Sandra Gofinet Pasoto, André Silva Franco, Clóvis A. Silva, et al.
Expert Review of Clinical Immunology (2024) Vol. 20, Iss. 10, pp. 1149-1167
Closed Access | Times Cited: 1
A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report
Xin Zhang, Bixia Gao, Cuiyan Guo, et al.
BMC Geriatrics (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 3
Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials
Shamsher Khan, Takefumi Komiya
Asian Pacific Journal of Cancer Prevention (2023) Vol. 24, Iss. 1, pp. 331-336
Open Access | Times Cited: 3
Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: An integrative review
Júlia de Almeida Santos Freitas, Maria Teresita Bendicho, Aníbal de Freitas Santos Júnior
Journal of Oncology Pharmacy Practice (2023)
Closed Access | Times Cited: 3
Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
Matthew R. Pincus, Miriam Silberstein, Nitzan Zohar, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1144-1144
Open Access
Retrospective identification of the first cord blood–transplanted severe aplastic anemia in a STAT1-associated chronic mucocutaneous candidiasis family: case report, review of literature and pathophysiologic background
Franz‐Martin Fink, R. Höpfl, Martina Witsch‐Baumgartner, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
T peripheral helper (Tph) cells, a marker of immune activation in cancer and autoimmune disorders
Celia del Carmen Crespo Oliva, Marilyne Labrie, Hugues Allard‐Chamard
Clinical Immunology (2024) Vol. 266, pp. 110325-110325
Open Access
Changes in the Levels of Soluble Programmed Death Molecule-Ligand 2 (sPD-L2) in the Peripheral Blood of Systemic Lupus Erythematosus and Their Clinical Significance
东青 周
Advances in Clinical Medicine (2024) Vol. 14, Iss. 05, pp. 1211-1222
Closed Access
Hydroxyurea-Associated Relapsing Polychondritis in a Patient With Myeloproliferative Neoplasm
İrfan Yavaşoğlu, Atakan Turgutkaya, Ali Zahit Bolaman
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 5, pp. 557-558
Closed Access | Times Cited: 1
Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy?
Kavina Shah, Maria Leandro, Mark S. Cragg, et al.
(2023)
Open Access | Times Cited: 1
An immunomodulating peptide with potential to suppress tumour growth and autoimmunity
Michael Agrez, Christopher Chandler, Kristofer J. Thurecht, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access
Page 1

Scroll to top